Aerovate Therapeutics sees $67.6M-$69.6M dividend in connection with Jade
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2025
0mins
Should l Buy ?
Merger and Cash Dividend Announcement: Aerovate Therapeutics plans to declare a cash dividend of approximately $67.6M-$69.6M for pre-Merger stockholders in connection with its merger with Jade Biosciences, pending board approval.
Upcoming Stockholder Meeting: A special meeting for Aerovate stockholders is scheduled for April 16 to vote on the merger, with the closing expected by April 30, subject to stockholder approval and other conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
